Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 4Withdrawn 1Terminated 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 3NET 1Gastrointestinal 1

Conditions

Neuroendocrine Tumors 19Carcinoid Tumor 5Pheochromocytoma 4Paraganglioma 3Gastro-enteropancreatic neuroendocrine tumor 3Vipoma 2Neoplasms 2Insulinoma 2Carcinoma, Merkel Cell 2Zollinger-Ellison Syndrome 1Somatostatinoma 1Small Cell Lung Carcinoma 1Serotonin Syndrome 1Pancreatic Neoplasms 1Non functioning pancreatic endocrine tumor 1Neuroblastoma 1Neoplasms, Unknown Primary 1Neoplasms, Cystic, Mucinous, and Serous 1Multiple Endocrine Neoplasia Type 2b 1Multiple Endocrine Neoplasia Type 2a 1Multiple Endocrine Neoplasia Type 1 1Lung Neoplasms 1Liver Neoplasms 1Hypoglycemia 1Glucagonoma 1Gastrinoma 1Diarrhea 1Carcinoma, Medullary 1Cachexia 1Adrenal Gland Neoplasms 1

Interventions

177Lu-octreotide, DOTA(0)-Tyr(3)- 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Gastrinoma × NET × Clear all
NCT04915144 2023-02-21

177Lu-DOTATOC for the Treatment of Patients With Somatostatin Receptor Positive NETs

British Columbia Cancer Agency

Phase 2 Withdrawn
EndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor, Carcinoid Tumor, Vipoma, Insulinoma, Gastrinoma, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡